A new trading day began on Friday, with Immunovant Inc (NASDAQ: IMVT) stock price down -7.60% from the previous day of trading, before settling in for the closing price of $15.78. IMVT’s price has ranged from $14.90 to $34.47 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -49.95%. With a float of $69.37 million, this company’s outstanding shares have now reached $147.20 million.
The firm has a total of 207 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.4%, operating margin of -27013.67%, and the pretax margin is -25478.07%.
Immunovant Inc (IMVT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Immunovant Inc is 59.16%, while institutional ownership is 49.43%. The most recent insider transaction that took place on Mar 07 ’25, was worth 156,769. In this transaction Director of this company sold 8,000 shares at a rate of $19.60, taking the stock ownership to the 91,913 shares. Before that another transaction happened on Mar 07 ’25, when Company’s Director proposed sale 8,000 for $19.52, making the entire transaction worth $156,160.
Immunovant Inc (IMVT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -49.95% per share during the next fiscal year.
Immunovant Inc (NASDAQ: IMVT) Trading Performance Indicators
Here are Immunovant Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.62, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -3.06 in one year’s time.
Technical Analysis of Immunovant Inc (IMVT)
Analysing the last 5-days average volume posted by the [Immunovant Inc, IMVT], we can find that recorded value of 3.19 million was better than the volume posted last year of 1.6 million. As of the previous 9 days, the stock’s Stochastic %D was 17.60%. Additionally, its Average True Range was 1.31.
During the past 100 days, Immunovant Inc’s (IMVT) raw stochastic average was set at 2.40%, which indicates a significant decrease from 6.69% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.65% in the past 14 days, which was higher than the 57.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.66, while its 200-day Moving Average is $26.17. Now, the first resistance to watch is $15.45. This is followed by the second major resistance level at $16.31. The third major resistance level sits at $16.96. If the price goes on to break the first support level at $13.94, it is likely to go to the next support level at $13.29. Should the price break the second support level, the third support level stands at $12.43.
Immunovant Inc (NASDAQ: IMVT) Key Stats
With a market capitalization of 2.48 billion, the company has a total of 169,861K Shares Outstanding. Currently, annual sales are 0 K while annual income is -259,340 K. The company’s previous quarter sales were 0 K while its latest quarter income was -111,120 K.
